Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kristensen, Lasse S ^a   Kjeldsen, Tina E ^a   Hager, Henrik ^b   Hansen, Lise L ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CADMA; Colorectal Cancer; DNA mutational analyses; EGFR; KRAS

Indexed keywords

DNA;

ADULT; ALLELE; AMPLICON; ARTICLE; COLORECTAL CANCER; COMPETITIVE AMPLIFICATION OF DIFFERENTIALLY MELTING AMPLICON; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA;

EID: 84869867412     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-548     Document Type: Article

References (23)

1. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 2010, 8(9):1175-1187. 10.1158/1541-7786.MCR-10-0264, 20693306.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J clin Oncol: Off J Am Soc Clin Oncol 2008, 26(10):1626-1634.
3. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8):3992-3995. 10.1158/0008-5472.CAN-06-0191, 16618717.
4. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA: J Am Med Assoc 2010, 304(16):1812-1820.
5. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go?. Nat rev Clin Oncol 2012, 9(2):87-97.
6. Kristensen LS, Daugaard IL, Christensen M, Hamilton-Dutoit S, Hager H, Hansen LL. Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. Hum Mutat 2010, 31(12):1366-1373. 10.1002/humu.21358, 20848649.
7. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008, 14(5):579-584. 10.1038/nm1708, 18408729.
8. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J mol diagn: JMD 2009, 11(6):543-552. 10.2353/jmoldx.2009.090057, 2765753, 19815694.
9. Kristensen LS, Andersen GB, Hager H, Hansen LL. Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by high-resolution melting analysis. Hum Mutat 2012, 33(1):264-271. 10.1002/humu.21598, 21901793.
10. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol diagn: JMD 2011, 13(1):23-28. 10.1016/j.jmoldx.2010.11.007, 3070579, 21227391.
11. Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998, 106(3):371-377.
12. Kristensen LS, Dobrovic A. Direct genotyping of single nucleotide polymorphisms in methyl metabolism genes using probe-free high-resolution melting analysis. Cancer epidemiol, biomark & prev: pub Am Assoc Cancer Res, cospons Am Soc Prev Oncol 2008, 17(5):1240-1247.
13. Lade-Keller J, Munck KR, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, Hager H, Kristensen LS. Evaluation of BRAF Mutation Testing Methodologies in Formalin Fixed Paraffin Embedded (FFPE) Cutaneous Melanomas. J Mol Diagnost 2012, in press..
14. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin cancer res: off j Am Assoc Cancer Res 2011, 17(14):4901-4914.
15. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, Karkavelas G. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009, 4(11):e7746. 10.1371/journal.pone.0007746, 2768905, 19888477.
16. Tol J, Dijkstra JR, Vink-Borger ME, Nagtegaal ID, Punt CJ, Van Krieken JH, Ligtenberg MJ. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J cell mol med 2010, 14(8):2122-2131.
17. Milbury CA, Li J, Makrigiorgos GM. PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem 2009, 55(4):632-640. 10.1373/clinchem.2008.113035, 2811432, 19201784.
18. Wittwer CT. High-resolution DNA melting analysis: advancements and limitations. Hum Mutat 2009, 30(6):857-859. 10.1002/humu.20951, 19479960.
19. Milbury CA, Li J, Liu P, Makrigiorgos GM. COLD-PCR: improving the sensitivity of molecular diagnostics assays. Expert Rev Mol Diagn 2011, 11(2):159-169. 10.1586/erm.10.115, 3111913, 21405967.
20. Milbury CA, Li J, Makrigiorgos GM. Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations. Nucleic Acids Res 2011, 39(1):e2. 10.1093/nar/gkq899, 3017621, 20937629.
21. Yu D, Mukai M, Liu Q, Steinman CR. Specific inhibition of PCR by non-extendable oligonucleotides using a 5' to 3' exonuclease-deficient DNA polymerase. Biotechniques 1997, 23(4):714-716. 718-720..
22. Dominguez PL, Kolodney MS. Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 2005, 24(45):6830-6834. 10.1038/sj.onc.1208832, 16116485.
23. Huang Q, Wang GY, Huang JF, Zhang B, Fu WL. High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles. Mol cell probes 2010, 24(6):376-380. 10.1016/j.mcp.2010.07.010, 20732413.